S&P 500   4,289.33 (-0.24%)
DOW   33,519.45 (-0.44%)
QQQ   358.09 (+0.02%)
AAPL   171.13 (+0.26%)
MSFT   315.92 (+0.73%)
META   301.96 (-0.66%)
GOOGL   130.95 (-1.03%)
AMZN   126.82 (+0.67%)
TSLA   249.00 (+1.06%)
NVDA   435.13 (+0.98%)
NIO   8.95 (+0.45%)
BABA   86.88 (+1.57%)
AMD   103.28 (+0.51%)
T   14.96 (-0.33%)
F   12.42 (-1.11%)
MU   67.76 (+3.93%)
CGC   0.79 (-2.65%)
GE   110.15 (-1.95%)
DIS   80.61 (+0.60%)
AMC   8.02 (+2.95%)
PFE   33.09 (+3.12%)
PYPL   58.24 (+0.10%)
NFLX   376.86 (+0.13%)
S&P 500   4,289.33 (-0.24%)
DOW   33,519.45 (-0.44%)
QQQ   358.09 (+0.02%)
AAPL   171.13 (+0.26%)
MSFT   315.92 (+0.73%)
META   301.96 (-0.66%)
GOOGL   130.95 (-1.03%)
AMZN   126.82 (+0.67%)
TSLA   249.00 (+1.06%)
NVDA   435.13 (+0.98%)
NIO   8.95 (+0.45%)
BABA   86.88 (+1.57%)
AMD   103.28 (+0.51%)
T   14.96 (-0.33%)
F   12.42 (-1.11%)
MU   67.76 (+3.93%)
CGC   0.79 (-2.65%)
GE   110.15 (-1.95%)
DIS   80.61 (+0.60%)
AMC   8.02 (+2.95%)
PFE   33.09 (+3.12%)
PYPL   58.24 (+0.10%)
NFLX   376.86 (+0.13%)
S&P 500   4,289.33 (-0.24%)
DOW   33,519.45 (-0.44%)
QQQ   358.09 (+0.02%)
AAPL   171.13 (+0.26%)
MSFT   315.92 (+0.73%)
META   301.96 (-0.66%)
GOOGL   130.95 (-1.03%)
AMZN   126.82 (+0.67%)
TSLA   249.00 (+1.06%)
NVDA   435.13 (+0.98%)
NIO   8.95 (+0.45%)
BABA   86.88 (+1.57%)
AMD   103.28 (+0.51%)
T   14.96 (-0.33%)
F   12.42 (-1.11%)
MU   67.76 (+3.93%)
CGC   0.79 (-2.65%)
GE   110.15 (-1.95%)
DIS   80.61 (+0.60%)
AMC   8.02 (+2.95%)
PFE   33.09 (+3.12%)
PYPL   58.24 (+0.10%)
NFLX   376.86 (+0.13%)
S&P 500   4,289.33 (-0.24%)
DOW   33,519.45 (-0.44%)
QQQ   358.09 (+0.02%)
AAPL   171.13 (+0.26%)
MSFT   315.92 (+0.73%)
META   301.96 (-0.66%)
GOOGL   130.95 (-1.03%)
AMZN   126.82 (+0.67%)
TSLA   249.00 (+1.06%)
NVDA   435.13 (+0.98%)
NIO   8.95 (+0.45%)
BABA   86.88 (+1.57%)
AMD   103.28 (+0.51%)
T   14.96 (-0.33%)
F   12.42 (-1.11%)
MU   67.76 (+3.93%)
CGC   0.79 (-2.65%)
GE   110.15 (-1.95%)
DIS   80.61 (+0.60%)
AMC   8.02 (+2.95%)
PFE   33.09 (+3.12%)
PYPL   58.24 (+0.10%)
NFLX   376.86 (+0.13%)

Merus (MRUS) Stock Forecast, Price & News

$23.38
-1.09 (-4.45%)
(As of 01:26 PM ET)
Compare
Today's Range
$22.60
$24.51
50-Day Range
$20.13
$26.28
52-Week Range
$12.03
$27.70
Volume
145,428 shs
Average Volume
329,794 shs
Market Capitalization
$1.17 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$44.33

Merus MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
89.6% Upside
$44.33 Price Target
Short Interest
Bearish
8.62% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.12) to ($2.86) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

494th out of 972 stocks

Pharmaceutical Preparations Industry

229th out of 451 stocks


MRUS stock logo

About Merus (NASDAQ:MRUS) Stock

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

MRUS Price History

MRUS Stock News Headlines

10 Analysts Have This to Say About Merus
This Stock's a Sleeping Giant
The stock everyone has their eye on - discover why it's the talk of the investment world.
Merus NV (MRUS): A Deep Dive into Its Overvalued Status
Will Merus (NASDAQ:MRUS) Spend Its Cash Wisely?
This Stock's a Sleeping Giant
The stock everyone has their eye on - discover why it's the talk of the investment world.
H.C. Wainwright Reaffirms Their Buy Rating on Merus (MRUS)
Expert Ratings for Merus
Analyst Expectations for Merus's Future
Merus appoints CFO
Where Merus Stands With Analysts
See More Headlines
Receive MRUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merus and its competitors with MarketBeat's FREE daily newsletter.

MRUS Company Calendar

Last Earnings
8/07/2023
Today
9/29/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MRUS
Fax
N/A
Employees
164
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$44.33
High Stock Price Forecast
$49.00
Low Stock Price Forecast
$35.00
Forecasted Upside/Downside
+81.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

Net Income
$-131,190,000.00
Net Margins
-432.68%
Pretax Margin
-428.44%

Debt

Sales & Book Value

Annual Sales
$41.59 million
Book Value
$5.34 per share

Miscellaneous

Free Float
47,715,000
Market Cap
$1.22 billion
Optionable
Not Optionable
Beta
0.84
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Sven Ante Lundberg M.D. (Age 60)
    CEO, Pres & Exec. Director
    Comp: $953.06k
  • Mr. Gregory D. Perry (Age 63)
    CFO & Principal Financial Officer
    Comp: $63.76k
  • Mr. Peter B. Silverman J.D. (Age 45)
    EVP, Company Sec., COO, Gen. Counsel, Chief Intellectual Property Officer & Head of US Legal
    Comp: $601.19k
  • Dr. Hui Liu Ph.D. (Age 56)
    Chief Bus. Officer, Exec. VP & Head of Merus U.S.
    Comp: $597.7k
  • Dr. Andrew Joe M.D. (Age 57)
    Chief Medical Officer & Sr. VP
    Comp: $692.74k
  • Dr. Hennie Hoogenboom
    Co-Founder and Scientific Advisor
  • Harry Shuman
    Chief Accounting Officer
  • Mr. Cornelis Adriaan de Kruif Ph.D. (Age 58)
    CTO & Exec. VP
  • Dr. Cecilia Anna Wilhelmina Geuijen Ph.D.
    Chief Scientific Officer & Sr. VP
  • Ms. Jillian Connell
    VP of Investor Relations & Corp. Communications













MRUS Stock - Frequently Asked Questions

Should I buy or sell Merus stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MRUS shares.
View MRUS analyst ratings
or view top-rated stocks.

What is Merus' stock price forecast for 2023?

10 Wall Street analysts have issued 12 month price objectives for Merus' stock. Their MRUS share price forecasts range from $35.00 to $49.00. On average, they anticipate the company's share price to reach $44.33 in the next twelve months. This suggests a possible upside of 81.2% from the stock's current price.
View analysts price targets for MRUS
or view top-rated stocks among Wall Street analysts.

How have MRUS shares performed in 2023?

Merus' stock was trading at $15.47 at the start of the year. Since then, MRUS shares have increased by 58.2% and is now trading at $24.47.
View the best growth stocks for 2023 here
.

When is Merus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our MRUS earnings forecast
.

How were Merus' earnings last quarter?

Merus (NASDAQ:MRUS) posted its earnings results on Monday, August, 7th. The biotechnology company reported ($0.66) EPS for the quarter, beating analysts' consensus estimates of ($0.86) by $0.20. The biotechnology company earned $10.48 million during the quarter, compared to the consensus estimate of $10.38 million. Merus had a negative net margin of 432.68% and a negative trailing twelve-month return on equity of 69.89%.

What ETFs hold Merus' stock?

ETFs with the largest weight of Merus (NASDAQ:MRUS) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Invesco Nasdaq Future Gen 200 ETF (QQQS).

What other stocks do shareholders of Merus own?
When did Merus IPO?

(MRUS) raised $64 million in an IPO on Thursday, May 19th 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.

What is Merus' stock symbol?

Merus trades on the NASDAQ under the ticker symbol "MRUS."

How do I buy shares of Merus?

Shares of MRUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Merus' stock price today?

One share of MRUS stock can currently be purchased for approximately $24.47.

How much money does Merus make?

Merus (NASDAQ:MRUS) has a market capitalization of $1.22 billion and generates $41.59 million in revenue each year. The biotechnology company earns $-131,190,000.00 in net income (profit) each year or ($3.86) on an earnings per share basis.

How many employees does Merus have?

The company employs 164 workers across the globe.

How can I contact Merus?

Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The official website for the company is www.merus.nl. The biotechnology company can be reached via phone at (130) 253-8800 or via email at enquiries@merus.nl.

This page (NASDAQ:MRUS) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -